A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma

INTRODUCTION: A combination of cetuximab and sorafenib in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) were assessed for potential benefit. MATERIAL AND METHODS: In a randomized phase II study, R/M HNSCC patients were treated with cetuximab 400mg/m(2)...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oral Oncol
Autors principals: Gilbert, Jill, Schell, Michael J., Zhao, Xiuhua, Murphy, Barbara, Tanvetyanon, Tawee, Leon, Marino E., Hayes, D. Neil, Haigentz, Missak, Saba, Nabil, Nieva, Jorge, Bishop, Justin, Sidransky, David, Ravi, Rajani, Bedi, Atul, Chung, Christine H.
Format: Artigo
Idioma:Inglês
Publicat: 2015
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4459134/
https://ncbi.nlm.nih.gov/pubmed/25593015
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.oraloncology.2014.12.011
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars